Tsc2 is a molecular checkpoint controlling osteoblast development and glucose homeostasis

Molecular and Cellular Biology

Volumn 34, Issue 10, 2014, Pages 1850-1862

  Riddle, Ryan C ^a,b   Frey, Julie L ^a   Tomlinson, Ryan E ^a   Ferron, Mathieu ^c,d   Li, Yuanyuan ^a   DiGirolamo, Douglas J ^a   Faugere, Marie Claude ^e   Hussain, Mehboob A ^a   Karsenty, Gerard ^f   Clemens, Thomas L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF KENTUCKY   (United States)

^f New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; OSTEOCALCIN; TUBERIN;

AGE; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METABOLISM; CELL MATURATION; CONTROLLED STUDY; ENERGY BALANCE; ENERGY METABOLISM; GENE; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SYNTHESIS; MOUSE; NONHUMAN; NUTRIENT; OBESITY; OSTEOBLAST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TSC2 GENE;

ANIMALS; BONE AND BONES; CELL DIFFERENTIATION; CELLS, CULTURED; GLUCOSE; HOMEOSTASIS; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCALCIN; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; X-RAY MICROTOMOGRAPHY;

EID: 84899139279     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00075-14     Document Type: Article

References (57)

1. Karsenty G. 2006. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 4:341-348. http://dx.doi.org/10.1016/j.cmet.2006.10.008.
2. Fukumoto S, Martin TJ. 2009. Bone as an endocrine organ. Trends Endocrinol. Metab. 20:230-236. http://dx.doi.org/10.1016/j.tem.2009.02.001.
3. Karsenty G, Oury F. 2012. Biology without walls: the novel endocrinology of bone. Annu. Rev. Physiol. 74:87-105. http://dx.doi.org/10.1146/annurev-physiol-020911-153233.
4. Spiegelman BM, Flier JS. 2001. Obesity and the regulation of energy balance. Cell 104:531-543. http://dx.doi.org/10.1016/S0092-8674(01)00240-9.
5. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. 2000. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197-207. http://dx.doi.org/10.1016/S0092-8674(00)81558-5.
6. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317. http://dx.doi.org/10.1016/S0092-8674(02)01049-8.
7. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. 2007. Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469. http://dx.doi.org/10.1016/j.cell.2007.05.047.
8. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere MC, Aja S, Hussain MA, Bruning JC, Clemens TL. 2010. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142:309-319. http://dx.doi.org/10.1016/j.cell.2010.06.002.
9. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G. 2010. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142:296-308. http://dx.doi.org/10.1016/j.cell.2010.06.003.
10. Rached MT, Kode A, Silva BC, Jung DY, Gray S, Ong H, Paik JH, DePinho RA, Kim JK, Karsenty G, Kousteni S. 2010. FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J. Clin. Invest. 120:357-368. http://dx.doi.org/10.1172/JCI39901.
11. Kode A, Mosialou I, Silva BC, Joshi S, Ferron M, Rached MT, Kousteni S. 2012. FoxO1 protein cooperates with ATF4 protein in osteoblasts to control glucose homeostasis. J. Biol. Chem. 287:8757-8768. http://dx.doi.org/10.1074/jbc.M111.282897.
12. Whiteman EL, Cho H, Birnbaum MJ. 2002. Role of Akt/protein kinase B in metabolism. Trends Endocrinol. Metab. 13:444-451. http://dx.doi.org/10.1016/S1043-2760(02)00662-8.
13. Wullschleger S, Loewith R, Hall MN. 2006. TOR signaling in growth and metabolism. Cell 124:471-484. http://dx.doi.org/10.1016/j.cell.2006.01.016.
14. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G. 2003. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11:1457-1466. http://dx.doi.org/10.1016/S1097-2765(03)00220-X.
15. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. 2003. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13:1259-1268. http://dx.doi.org/10.1016/S0960-9822(03)00506-2.
16. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10:151-162. http://dx.doi.org/10.1016/S1097-2765(02)00568-3.
17. Inoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:648-657. http://dx.doi.org/10.1038/ncb839.
18. Hernandez O, Way S, McKenna J, III, Gambello MJ. 2007. Generation of a conditional disruption of the Tsc2 gene. Genesis 45:101-106. http://dx.doi.org/10.1002/dvg.20271.
19. Lang CH, Frost RA, Bronson SK, Lynch CJ, Vary TC. 2010. Skeletal muscle protein balance in mTOR heterozygous mice in response to inflammation and leucine. Am. J. Physiol. Endocrinol. Metab. 298:E1283-E1294. http://dx.doi.org/10.1152/ajpendo.00676.2009.
20. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. 2002. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem. 277:44005-44012. http://dx.doi.org/10.1074/jbc.M208265200.
21. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2:595-610.
22. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. 2010. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 25:1468-1486. http://dx.doi.org/10.1002/jbmr.141.
23. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. 2013. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 28:2-17. http://dx.doi.org/10.1002/jbmr.1805.
24. Hussain MA, Porras DL, Rowe MH, West JR, Song WJ, Schreiber WE, Wondisford FE. 2006. Increased pancreatic beta-cell proliferation mediated by CREB binding protein gene activation. Mol. Cell. Biol. 26:7747-7759. http://dx.doi.org/10.1128/MCB.02353-05.
25. Fulzele K, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. 2007. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J. Biol. Chem. 282:25649-25658. http://dx.doi.org/10.1074/jbc.M700651200.
26. Ferron M, Wei J, Yoshizawa T, Ducy P, Karsenty G. 2010. An ELISAbased method to quantify osteocalcin carboxylation in mice. Biochem. Biophys. Res. Commun. 397:691-696. http://dx.doi.org/10.1016/j.bbrc.2010.06.008.
27. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, Olson EN, Justice MJ, Karsenty G. 2004. A twist code determines the onset of osteoblast differentiation. Dev. Cell 6:423-435. http://dx.doi.org/10.1016/S1534-5807(04)00058-9.
28. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213-223. http://dx.doi.org/10.1083/jcb.200403069.
29. Shah OJ, Wang Z, Hunter T. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14:1650-1656. http://dx.doi.org/10.1016/j.cub.2004.08.026.
30. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, Hotamisligil GS. 2008. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 29:541-551. http://dx.doi.org/10.1016/j.molcel.2007.12.023.
31. Bain J, McLauchlan H, Elliott M, Cohen P. 2003. The specificities of protein kinase inhibitors: an update. Biochem. J. 371:199-204. http://dx.doi.org/10.1042/BJ20021535.
32. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS. 2004. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457-461. http://dx.doi.org/10.1126/science.1103160.
33. Aguirre V, Uchida T, Yenush L, Davis R, White MF. 2000. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 275:9047-9054. http://dx.doi.org/10.1074/jbc.275.12.9047.
34. Granner D, Andreone T, Sasaki K, Beale E. 1983. Inhibition of transcription of the phosphoenolpyruvate carboxykinase gene by insulin. Nature 305:549-551. http://dx.doi.org/10.1038/305549a0.
35. Iynedjian PB, Pilot PR, Nouspikel T, Milburn JL, Quaade C, Hughes S, Ucla C, Newgard CB. 1989. Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. Proc. Natl. Acad. Sci. U. S. A. 86:7838-7842. http://dx.doi.org/10.1073/pnas.86.20.7838.
36. Huang B, Wu P, Bowker-Kinley MM, Harris RA. 2002. Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferatoractivated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 51:276-283. http://dx.doi.org/10.2337/diabetes.51.2.276.
37. Pi M, Wu Y, Quarles LD. 2011. GPRC6A mediates responses to osteocalcin in beta-cells in vitro and pancreas in vivo. J. Bone Miner. Res. 26:1680-1683. http://dx.doi.org/10.1002/jbmr.390.
38. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL, Ducy P, Karsenty G. 2011. Endocrine regulation of male fertility by the skeleton. Cell 144:796-809. http://dx.doi.org/10.1016/j.cell.2011.02.004.
39. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL. 2006. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955-968. http://dx.doi.org/10.1016/j.cell.2006.06.055.
40. Inoki K, Zhu T, Guan KL. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590. http://dx.doi.org/10.1016/S0092-8674(03)00929-2.
41. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC, Jr. 2008. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity. Mol. Cell. Biol. 28:61-70. http://dx.doi.org/10.1128/MCB.01405-07.
42. Huang J, Manning BD. 2008. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412:179-190. http://dx.doi.org/10.1042/BJ20080281.
43. Liu X, Bruxvoort KJ, Zylstra CR, Liu J, Cichowski R, Faugere MC, Bouxsein ML, Wan C, Williams BO, Clemens TL. 2007. Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc. Natl. Acad. Sci. U. S. A. 104:2259-2264. http://dx.doi.org/10.1073/pnas.0604153104.
44. Cornish J, Callon KE, Reid IR. 1996. Insulin increases histomorphometric indices of bone formation in vivo. Calcif. Tissue Int. 59:492-495. http://dx.doi.org/10.1007/BF00369216.
45. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. 2000. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J. Endocrinol. Invest. 23:295-303.
46. Thrailkill KM. 2000. Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol. Ther. 2:69-80. http://dx.doi.org/10.1089/152091599316775.
47. Osborne JP. 1988. Diagnosis of tuberous sclerosis. Arch. Dis. Child. 63:1423-1425. http://dx.doi.org/10.1136/adc.63.12.1423.
48. Bernauer TA, Mirowski GW, Caldemeyer KS. 2001. Tuberous sclerosis. Part II. Musculoskeletal and visceral findings. J. Am. Acad. Dermatol. 45:450-452. http://dx.doi.org/10.1067/mjd.2001.111626.
49. Smith TK, Gregersen GG, Samilson RL. 1969. Orthopaedic problems associated with tuberous sclerosis. J. Bone Joint Surg. Am. 51:97-102.
50. Gasparetto EL, de Carvalho Neto A, Bruck I, Antoniuk S. 2003. Tuberous sclerosis and fibrous dysplasia. Am. J. Neuroradiol. 24:835-837.
51. Breningstall GN, Faerber EN, Kolanu R. 1988. Fibrous dysplasia in a patient with tuberous sclerosis. J. Child Neurol. 3:131-134. http://dx.doi.org/10.1177/088307388800300211.
52. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. 2002. A central role for JNK in obesity and insulin resistance. Nature 420:333-336. http://dx.doi.org/10.1038/nature01137.
53. Ferron M, Hinoi E, Karsenty G, Ducy P. 2008. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. U. S. A. 105:5266-5270. http://dx.doi.org/10.1073/pnas.0711119105.
54. Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. 2012. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 50:568-575. http://dx.doi.org/10.1016/j.bone.2011.04.017.
55. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. 2006. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell 24:185-197. http://dx.doi.org/10.1016/j.molcel.2006.09.019.
56. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. 2008. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol. Cell 30:701-711. http://dx.doi.org/10.1016/.molcel.2008.04.027.
57. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. 2001. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21:952-965. http://dx.doi.org/10.1128/MCB.21.3.952-965.2001.